BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 19, 2006
View Archived Issues
Results of phase I and II studies of kinesin spindle protein inhibitors reported
Read More
Repeated CNTO-328 dosing feasible in patients with hematological malignancies
Read More
Long-lasting responses seen with AP-12009 in anaplastic astrocytoma and glioblastoma
Read More
Milataxel investigated in phase I and II trials in cancer patients
Read More
Studies detail CP-675206 dosing and activity in melanoma patients
Read More
Phase II liver cancer study to evaluate Avastin with chemoembolization
Read More
PhytoMedical Technologies and Iowa State University sign license agreement
Read More
Pfizer completes acquisition of fesoterodine rights from Schwarz Pharma
Read More
rEV-131 studied in pivotal Canadian trial for allergic rhinitis
Read More
Supernus signs agreement with United Therapeutics for UT-15C
Read More
New phase I study evaluates PXD-101 with cis-retinoic acid for solid tumors
Read More
Enrollment closing for phase II study of HyCAMP in metastatic colorectal cancer
Read More
Phase III studies of Puricase begin dosing
Read More
BiPar Sciences advances compounds after new financing
Read More
Series A financing to fund development of Danube's oral glaucoma therapy
Read More
Cobalis plans twin phase III studies for PreHistin
Read More
Norwegian hospitals to study GV-1001 for NSCLC
Read More
Orphan drug status for Surfaxin in prevention of bronchopulmonary dysplasia
Read More
European phase III study to begin for SP-01A in HIV
Read More
FAV-201 cleared to begin phase I/II study in CTCL
Read More
Enrollment completed in celgosivir phase IIb combination study in HCV
Read More
Locus submits IND for phase I study of lead compound LP-261
Read More
ARQ-501 studied with docetaxel and gemcitabine in refractory solid tumors
Read More
Sanctura XR reduces symptoms of overactive bladder
Read More
AN-0128 demonstrates activity in atopic dermatitis
Read More
Parion Sciences presents novel ENaC blocker as clinical candidate for CF
Read More
New PPARgamma modulators prepared and tested at Galderma
Read More
Pfizer report on novel NEP inhibitor for the treatment of FSAD
Read More
New agents with potential in the treatment of cancer imparted in recent patents
Read More
Hycamtin approved for use with cisplatin in cervical cancer
Read More
Promising preclinical data of S-40755 in the long-term control of glycemia in diabetic rodent models
Read More
Recombinant human fibroblast growth factor-21 demonstrates antidiabetic potential in vivo
Read More